Biopharmaceutical company
Appears in 1 story
Advancing imapextide, a competing GLP-1 antagonist, in Phase IIa
Post-bariatric hypoglycemia has no FDA-approved treatment. Amylyx Pharmaceuticals just moved to change that: its Phase III LUCIDITY trial showed avexitide cut dangerous hypoglycemic events by 55% versus placebo (p=0.000003), and the company plans to file for FDA approval by year-end.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
